Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
复制标题
DOI：
10.1371/journal.pone.0163644
复制
发表时间：
2016-09-28
期刊：
影响因子：
3.7
通讯作者：
Nakao, Kazuhiko
中科院分区：
文献类型：
--
作者：
Hashimoto, Satoru;Yatsuhashi, Hiroshi;Nakao, Kazuhiko
背景与目的我们对接受无干扰素（IFN）直接作用抗病毒（DAA）治疗的慢性丙型肝炎患者在治疗早期进行血脂分析，我们试图找出导致患者血清低密度脂蛋白胆固醇（LDL-C）快速升高的因素，我们回顾性分析了在国立医院组织长崎医学中心治疗的100名连续HCV感染患者的病例：24例患者接受达卡他韦（DCV）和阿舒那匹韦（ASV）联合治疗（DCV/ASV）24周，另76例患者接受雷迪帕韦和索非布韦联合治疗（LDV/SOF）12周。Δ LDL-C定义为治疗开始后28天LDL-C水平的变化。结果LDV/SOF治疗组患者的LDL-C水平明显升高（87.45 ~ 122.5mg/dl; P < 0.01），LDL-C与病毒动力学等多种因素的关系不明显。
Background & AimWe performed lipid analyses at the early period of therapy in patients with chronic hepatitis C who underwent interferon (IFN)-free direct-acting antiviral (DAA) treatment, and we attempted to identify the factors that contributed to a rapid increase in the patients' serum low-density lipoprotein cholesterol (LDL-C) concentration.MethodsWe retrospectively analyzed the cases of 100 consecutive patients with HCV infection treated at the National Hospital Organization Nagasaki Medical Center: 24 patients underwent daclatasvir (DCV) and asunaprevir (ASV) combination therapy (DCV/ASV) for 24 weeks, and the other 76 patients underwent ledipasvir and sofosbuvir combination therapy (LDV/SOF) for 12 weeks. Delta LDL-C was defined as the changed in LDL-C level at 28 days from the start of therapy. To determine whether.LDL-C was associated with several kinds of factors including viral kinetics, we performed a stepwise multiple linear regression analysis.ResultsThe LDL-C levels in patients treated with LDV/SOF were markedly and significantly elevated (87.45 to 122.5 mg/dl; p